We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Dermatology

Journal Scan / Review · July 01, 2020

Risk of Dupilumab Use for Atopic Dermatitis During the COVID-19 Pandemic

Journal of the American Academy of Dermatology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of the American Academy of Dermatology
Assessing the Risk of Dupilumab Use for Atopic Dermatitis During the COVID-19 Pandemic
J Am Acad Dermatol 2020 Jun 10;[EPub Ahead of Print], DG Kearns, S Uppal, VS Chat, JJ Wu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading